Latest & greatest articles for mammography

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mammography or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mammography and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mammography

21. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening (Full text)

The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening An interval breast cancer is a cancer that emerges following a negative mammographic screen. This overview describes the epidemiology, and the radiological and biological characteristics of interval breast cancers in population mammography screening. Notwithstanding possible differences in ascertainment of interval breast cancers, there was broad variability in reported (...) characteristics and biomarker profile, and also survival outcomes, than screen-detected breast cancers; however, they have similar characteristics and prognosis as breast cancers occurring in non-screened women. There was limited evidence on the effect on interval breast cancer frequency and outcomes following transition from film to digital mammography screening.

2017 NPJ breast cancer PubMed

22. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening (...) in Women at Less Than High Risk for Breast Cancer Ontario Health Technology Advisory Committee Recommendation The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast magnetic resonance imaging (MRI) as an adjunct to screening mammography for women who are at less than high risk for breast cancer and who have no personal history of breast cancer Breast cancer is the most common cancer among Canadian women. The most common form of screening for breast cancer

2017 Health Quality Ontario

23. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women atless than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment (...) Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series

2017 Health Technology Assessment (HTA) Database.

24. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation

Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation Health Quality Ontario Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Quality Ontario. Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2016 Authors' conclusions The Ontario Health Technology Advisory Committee (OHTAC

2017 Health Technology Assessment (HTA) Database.

26. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). (PubMed)

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Women genetically predisposed to breast cancer often develop the disease at a young age when dense breast tissue reduces the sensitivity of X-ray mammography. Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening.We did a prospective multicentre cohort study in 649 (...) women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation. We recruited participants from 22 centres in the UK, and offered the women annual screening with CE MRI and mammography for 2-7 years.We diagnosed 35 cancers in the 649 women screened with both mammography and CE MRI (1881 screens): 19 by CE MRI only, six by mammography only, and eight by both, with two interval cases. Sensitivity was significantly higher for CE MRI (77

2017 Lancet

27. Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer

Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer Health Technology Assessment - Health Quality Ontario (HQO) Let's make our health system healthier Open Menu Quick Links Search Search A A A Evidence to Improve Care Share: Health Technology Assessment To continuously improve the quality of health care in Ontario, we use established scientific methods to analyze evidence and develop assessments of new

2016 Health Quality Ontario

28. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. (Full text)

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. The goal of screening mammography is to detect small malignant tumors before they grow large enough to cause symptoms. Effective screening should therefore lead to the detection of a greater number of small tumors, followed by fewer large tumors over time.We used data from the Surveillance, Epidemiology, and End Results (SEER) program, 1975 through 2012, to calculate the tumor-size distribution and size-specific (...) incidence of breast cancer among women 40 years of age or older. We then calculated the size-specific cancer case fatality rate for two time periods: a baseline period before the implementation of widespread screening mammography (1975 through 1979) and a period encompassing the most recent years for which 10 years of follow-up data were available (2000 through 2002).After the advent of screening mammography, the proportion of detected breast tumors that were small (invasive tumors measuring <2 cm

2016 NEJM PubMed

29. Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation

Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) Health Quality Ontario. Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2016 Authors' conclusions The Ontario Health Technology Advisory Committee recommends publicly funding screening breast ultrasound as an adjunct to screening mammography for high-risk women in whom magnetic resonance imaging (MRI) is contraindicated. The Ontario Health Technology Advisory Committee recommends against publicly funding screening

2016 Health Technology Assessment (HTA) Database.

30. Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment

Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Health Quality Ontario. Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 16(15). 2016 Authors' conclusions We found no evidence that evaluated the comparative effectiveness or diagnostic accuracy of screening breast ultrasound as an adjunct to mammography among average-risk women aged 50 years and over. In women at high risk of developing

2016 Health Technology Assessment (HTA) Database.

31. The impacts of public mammography screening on the relationship between socioeconomic status and cancer stage (Full text)

The impacts of public mammography screening on the relationship between socioeconomic status and cancer stage This study aimed to investigate the relationship between socioeconomic inequality and mortality following the introduction of a public mammography screening program in Norway by exploring the role of change in stage distribution as the mechanism for differences before and after the introduction of the screening program. Attained education level was used as a measure of socioeconomic (...) with primary school of -1.8 (-2.2 to -1.4) and -0.7 (-0.9 to -0.5) fewer deaths in favor of women with university education and secondary school, respectively. The results indicate reduced importance of cancer stage as a reason for differences in mortality by socioeconomic status after the introduction of a public mammography program.

2016 SSM - population health PubMed

32. Ultrasound as an Adjunct to Mammography for Breast Cancer Screening

Ultrasound as an Adjunct to Mammography for Breast Cancer Screening Health Quality Ontario The provincial advisor on the quality of health care in Ontario Let’s make our health system healthier Ultrasound as an Adjunct to Mammography for Breast Cancer Screening: OHTAC Recommendation ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATIONS ? The Ontario Health Technology Advisory Committee recommends publicly funding screening breast ultrasound as an adjunct to screening mammography for high (...) -risk women in whom magnetic resonance imaging (MRI) is contraindicated. ? The Ontario Health Technology Advisory Committee recommends against publicly funding screening breast ultrasound as an adjunct to screening mammography in women at average risk for breast cancer. RATIONALE FOR THE RECOMMENDATION DECISION Given the absence of evidence demonstrating benefit, 1 there was consensus among members of the Ontario Health Technology Advisory Committee (OHTAC) that adjunct screening breast ultrasound

2016 Health Quality Ontario

33. Systematic review of 3D mammography for breast cancer screening. (Full text)

Systematic review of 3D mammography for breast cancer screening. This review investigated the relative performance of digital breast tomosynthesis (DBT) (alone or with full field digital mammography (FFDM) or synthetic digital mammography) compared with FFDM alone for detecting breast cancer lesions in asymptomatic women. A systematic review was carried out according to systematic reviewing principles provided in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy

2016 Breast (Edinburgh, Scotland) PubMed

34. Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis. (PubMed)

Diagnostic performance of contrast-enhanced spectral mammography: Systematic review and meta-analysis. To estimate sensitivity and specificity of CESM for breast cancer diagnosis.Systematic review and meta-analysis of the accuracy of CESM in finding breast cancer in highly selected women. We estimated summary receiver operating characteristic curves, sensitivity and specificity according to quality criteria with QUADAS-2.Six hundred four studies were retrieved, 8 of these reporting on 920

2016 Breast (Edinburgh, Scotland)

35. Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women (Full text)

Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women Breast cancer is the most common cancer in Iranian women as is worldwide. Mammography screening has been introduced as a beneficial method for reducing mortality and morbidity of this disease.We developed an analytical model to assess the cost effectiveness of an organized mammography screening program in Iran for early detection of the breast cancer.This study is an economic evaluation of mammography (...) screening program among Iranian woman aged 40 - 70 years. A decision tree and Markov model were applied to estimate total quality adjusted life years (QALY) and lifetime costs.The results revealed that the incremental cost effectiveness ratio (ICER) of mammography screening in Iranian women in the first round was Int. $ 37,350 per QALY gained. The model showed that the ICER in the second and third rounds of screening program were Int. $ 141,641 and Int. $ 389,148 respectively.Study results identified

2016 Iranian journal of cancer prevention PubMed

36. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. (Full text)

Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Estimates of risk for radiation-induced breast cancer from mammography screening have not considered variation in dose exposure or diagnostic work-up after abnormal screening results.To estimate distributions of radiation-induced breast cancer incidence and mortality from digital mammography screening while considering exposure from screening and diagnostic mammography and dose (...) variation among women.2 simulation-modeling approaches.U.S. population.Women aged 40 to 74 years.Annual or biennial digital mammography screening from age 40, 45, or 50 years until age 74 years.Lifetime breast cancer deaths averted (benefits) and radiation-induced breast cancer incidence and mortality (harms) per 100,000 women screened.Annual screening of 100,000 women aged 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 deaths (CI, 11 to 23), relative

2016 Annals of Internal Medicine PubMed

37. Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data. (Full text)

Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data. Women screened with digital mammography may receive false-positive and false-negative results and subsequent imaging and biopsies. How these outcomes vary by age, time since the last screening, and individual risk factors is unclear.To determine factors associated with false-positive and false-negative digital mammography results, additional imaging (...) , and biopsies among a general population of women screened for breast cancer.Analysis of registry data.Participating facilities at 5 U.S. Breast Cancer Surveillance Consortium breast imaging registries with linkages to pathology databases and tumor registries.405,191 women aged 40 to 89 years screened with digital mammography between 2003 and 2011. A total of 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening.Rates of false-positive and false-negative results

2016 Annals of Internal Medicine PubMed

38. Recall Rates for Digital Mammography for Patients Undergoing Screening for Breast Cancer: Evidence-Based Guidelines

Recall Rates for Digital Mammography for Patients Undergoing Screening for Breast Cancer: Evidence-Based Guidelines Recall Rates for Digital Mammography for Patients Undergoing Screening for Breast Cancer: Evidence-Based Guidelines | CADTH.ca Find the information you need Recall Rates for Digital Mammography for Patients Undergoing Screening for Breast Cancer: Evidence-Based Guidelines Recall Rates for Digital Mammography for Patients Undergoing Screening for Breast Cancer: Evidence-Based (...) Guidelines Published on: September 30, 2015 Project Number: RB0917-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding appropriate recall for patients undergoing digital mammography for breast cancer screening? Key Message No relevant evidence-based guidelines were identified regarding appropriate recall for patients undergoing digital mammography for breast cancer screening. Tags false

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

39. Breast cancer screening and mammography: inform women

Breast cancer screening and mammography: inform women Prescrire IN ENGLISH - Spotlight ''Breast cancer screening and mammography: inform women '', 1 July 2015 {1} {1} {1} | | > > > Breast cancer screening and mammography: inform women Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Breast cancer screening and mammography: inform women Information (...) must be shared with women to help them decide whether or not to take part in breast cancer screening. In a series of articles published over the past year, Prescrire updated its analysis of the harm-benefit balance of breast cancer screening by mammography. In France, it is estimated that, overall, for every 1000 woman aged 50, around 72 women are diagnosed with breast cancer over a period of 20 years. In the 10 years following this diagnosis, around 13 of these women die from breast cancer, and 4

2015 Prescrire

40. Tomosynthesis (3D Mammography) for Breast Cancer Screening

Tomosynthesis (3D Mammography) for Breast Cancer Screening 1 Issue 135 ? May 2015 Issues in Emerging Health Technologies Summary ? Digital breast tomosynthesis (DBT) is a novel imaging technology that captures three- dimensional (3D) images of the breast. ? DBT can be used for screening or diagnosis. ? Seven recent, large screening studies that each enrolled more than 10,000 women showed that DBT can reduce the need to recall women for further testing compared with current two- dimensional (2D (...) Traditional two-dimensional (2D) mammography captures two static images of the breast. One particular shortcoming of 2D technology is the overlapping of breast images that can decrease accuracy of interpretation. With digital breast tomosynthesis (DBT), an X-ray beam sweeps in an arc of 15 to 50 degrees (depending on the manufacturer) across the breast, and an electronic detector digitally captures between nine and 25 X-ray projection images. 1-6 These images are generally captured in two views

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review